Ákos Nemecz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ákos Nemecz has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Pierre-Jean Corringer
Institut Pasteur, Université Paris Cité, CNRS UMR 3571, Channel-Receptors Unit
5 shared publications - Catherine Van Renterghem
Channel‐Receptors Unit, Institut Pasteur, CNRS UMR3571 Université Paris Cité Paris France
3 shared publications - Gabriel Ayme
Center for Technological Resources and Research, Antibody Engineering platform, Institut Pasteur, Université Paris Cité, CNRS UMR 3528
2 shared publications Gabrielle Dejean de la Bâtie
Institut Pasteur, Université Paris Cité, CNRS UMR 3571, Channel-Receptors Unit, Paris, France
2 shared publicationsKarima Medjebeur
Channel‐Receptors Unit, Institut Pasteur, CNRS UMR3571 Université Paris Cité Paris France
2 shared publicationsQimeng Li
Institut Pasteur, Université Paris Cité, CNRS UMR 3571, Channel-Receptors Unit, Paris, France
2 shared publications
Latest Publications
- Open Access
- 3 June 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (11) , 12286
Corrections to “VHH Nanobody Versatility against Pentameric Ligand-Gated Ion Channels”
- 3 June 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (11) , 12286
Open AccessCorrections to “VHH Nanobody Versatility against Pentameric Ligand-Gated Ion Channels”
- Open Access
- 3 June 2024
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 67 (11) , 8502-8518
VHH Nanobody Versatility against Pentameric Ligand-Gated Ion Channels
Pentameric ligand-gated ion channels provide rapid chemical-electrical signal transmission between cells in the central and peripheral nervous system. Their dysfunction is associated with many nervous system disorders. They are composed of five identical (homomeric receptors) or homologous (heteromeric receptors) subunits. VHH nanobodies, or single-chain antibodies, are the variable domain, VHH, of antibodies that are composed of the heavy chain only from camelids. Their unique structure results in many specific biochemical and biophysical properties that make them an excellent alternative to conventional antibodies. This Perspective explores the published VHH nanobodies which have been isolated against pentameric ligand-gated ion channel subfamilies. It outlines the genetic and chemical modifications available to alter nanobody function. An assessment of the available functional and structural data indicate that it is feasible to create therapeutic agents and impart, through their modification, a given desired modulatory effect of its target receptor for current stoichiometric-specific VHH nanobodies.
- 3 June 2024
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 67 (11) , 8502-8518
Open AccessVHH Nanobody Versatility against Pentameric Ligand-Gated Ion Channels
Pentameric ligand-gated ion channels provide rapid chemical-electrical signal transmission between cells in the central and peripheral nervous system. Their dysfunction is associated with many nervous system disorders. They are composed of five identical (homomeric receptors) or homologous (heteromeric receptors) subunits. VHH nanobodies, or single-chain antibodies, are the variable domain, VHH, of antibodies that are composed of the heavy chain only from camelids. Their unique structure results in many specific biochemical and biophysical properties that make them an excellent alternative to conventional antibodies. This Perspective explores the published VHH nanobodies which have been isolated against pentameric ligand-gated ion channel subfamilies. It outlines the genetic and chemical modifications available to alter nanobody function. An assessment of the available functional and structural data indicate that it is feasible to create therapeutic agents and impart, through their modification, a given desired modulatory effect of its target receptor for current stoichiometric-specific VHH nanobodies.
- Open Access
- 11 February 2024
- Published by Wiley in Physiological Reports
- Vol. 12 (3) , e15916
Short‐chain mono‐carboxylates as negative modulators of allosteric transitions in Gloeobacter violaceus ligand‐gated ion channel, and impact of a pre‐β5 strand (Loop Ω) double mutation on crotonate, not butyrate effect
Using the bacterial proton‐activated pentameric receptor‐channel Gloeobacter violaceus ligand‐gated ion channel (GLIC): (1) We characterize saturated, mono‐carboxylates as negative modulators of GLIC (as previously shown for crotonate; Alqazzaz et al., Biochemistry, 2016, 55, 5947). Butyrate and crotonate have indistinguishable properties regarding negative modulation of wt GLIC. (2) We identify a locus in the pre‐β5 strand (Loop Ω) whose mutation inverses the effect of the mono‐carboxylate crotonate from negative to positive modulation of the allosteric transitions, suggesting an involvement of the pre‐β5 strand in coupling the extracellular orthotopic receptor to pore gating. (3) As an extension to the previously proposed “in series” mechanism, we suggest that a orthotopic/orthosteric site—vestibular site—Loop Ω—β5‐β6 “sandwich”—Pro‐Loop/Cys‐Loop series may be an essential component of orthotopic/orthosteric compound‐elicited gating control in this pentameric ligand‐gated ion channel, on top of which compounds targeting the vestibular site may provide modulation.
- 11 February 2024
- Published by Wiley in Physiological Reports
- Vol. 12 (3) , e15916
Open AccessShort‐chain mono‐carboxylates as negative modulators of allosteric transitions in Gloeobacter violaceus ligand‐gated ion channel, and impact of a pre‐β5 strand (Loop Ω) double mutation on crotonate, not butyrate effect
Using the bacterial proton‐activated pentameric receptor‐channel Gloeobacter violaceus ligand‐gated ion channel (GLIC): (1) We characterize saturated, mono‐carboxylates as negative modulators of GLIC (as previously shown for crotonate; Alqazzaz et al., Biochemistry, 2016, 55, 5947). Butyrate and crotonate have indistinguishable properties regarding negative modulation of wt GLIC. (2) We identify a locus in the pre‐β5 strand (Loop Ω) whose mutation inverses the effect of the mono‐carboxylate crotonate from negative to positive modulation of the allosteric transitions, suggesting an involvement of the pre‐β5 strand in coupling the extracellular orthotopic receptor to pore gating. (3) As an extension to the previously proposed “in series” mechanism, we suggest that a orthotopic/orthosteric site—vestibular site—Loop Ω—β5‐β6 “sandwich”—Pro‐Loop/Cys‐Loop series may be an essential component of orthotopic/orthosteric compound‐elicited gating control in this pentameric ligand‐gated ion channel, on top of which compounds targeting the vestibular site may provide modulation.
- Open Access
- 25 May 2023
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 80 (6) , 1-17
Generation of nanobodies acting as silent and positive allosteric modulators of the α7 nicotinic acetylcholine receptor
The α7 nicotinic acetylcholine receptor (nAChR), a potential drug target for treating cognitive disorders, mediates communication between neuronal and non-neuronal cells. Although many competitive antagonists, agonists, and partial-agonists have been found and synthesized, they have not led to effective therapeutic treatments. In this context, small molecules acting as positive allosteric modulators binding outside the orthosteric, acetylcholine, site have attracted considerable interest. Two single-domain antibody fragments, C4 and E3, against the extracellular domain of the human α7-nAChR were generated through alpaca immunization with cells expressing a human α7-nAChR/mouse 5-HT3A chimera, and are herein described. They bind to the α7-nAChR but not to the other major nAChR subtypes, α4β2 and α3β4. E3 acts as a slowly associating positive allosteric modulator, strongly potentiating the acetylcholine-elicited currents, while not precluding the desensitization of the receptor. An E3–E3 bivalent construct shows similar potentiating properties but displays very slow dissociation kinetics conferring quasi-irreversible properties. Whereas, C4 does not alter the receptor function, but fully inhibits the E3-evoked potentiation, showing it is a silent allosteric modulator competing with E3 binding. Both nanobodies do not compete with α-bungarotoxin, localizing at an allosteric extracellular binding site away from the orthosteric site. The functional differences of each nanobody, as well as the alteration of functional properties through nanobody modifications indicate the importance of this extracellular site. The nanobodies will be useful for pharmacological and structural investigations; moreover, they, along with the extracellular site, have a direct potential for clinical applications.
- 25 May 2023
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 80 (6) , 1-17
Open AccessGeneration of nanobodies acting as silent and positive allosteric modulators of the α7 nicotinic acetylcholine receptor
The α7 nicotinic acetylcholine receptor (nAChR), a potential drug target for treating cognitive disorders, mediates communication between neuronal and non-neuronal cells. Although many competitive antagonists, agonists, and partial-agonists have been found and synthesized, they have not led to effective therapeutic treatments. In this context, small molecules acting as positive allosteric modulators binding outside the orthosteric, acetylcholine, site have attracted considerable interest. Two single-domain antibody fragments, C4 and E3, against the extracellular domain of the human α7-nAChR were generated through alpaca immunization with cells expressing a human α7-nAChR/mouse 5-HT3A chimera, and are herein described. They bind to the α7-nAChR but not to the other major nAChR subtypes, α4β2 and α3β4. E3 acts as a slowly associating positive allosteric modulator, strongly potentiating the acetylcholine-elicited currents, while not precluding the desensitization of the receptor. An E3–E3 bivalent construct shows similar potentiating properties but displays very slow dissociation kinetics conferring quasi-irreversible properties. Whereas, C4 does not alter the receptor function, but fully inhibits the E3-evoked potentiation, showing it is a silent allosteric modulator competing with E3 binding. Both nanobodies do not compete with α-bungarotoxin, localizing at an allosteric extracellular binding site away from the orthosteric site. The functional differences of each nanobody, as well as the alteration of functional properties through nanobody modifications indicate the importance of this extracellular site. The nanobodies will be useful for pharmacological and structural investigations; moreover, they, along with the extracellular site, have a direct potential for clinical applications.
- 27 April 2023
- Published by Wiley in The Journal of Physiology
- Vol. 601 (12) , 2447-2472
Fumarate as positive modulator of allosteric transitions in the pentameric ligand‐gated ion channel GLIC: requirement of an intact vestibular pocket
Gloeobacter violaceus ligand-gated ion channel (GLIC) is a prokaryotic orthologue of brain pentameric neurotransmitter receptors. Using whole-cell patch-clamp electrophysiology in a host cell line, we show that short-chain dicarboxylate compounds are positive modulators of pHo 5-evoked GLIC activity, with a rank order of action fumarate > succinate > malonate > glutarate. Potentiation by fumarate depends on intracellular pH, mainly as a result of a strong decrease of the pHo 5-evoked current when intracellular pH decreases. The modulating effect of fumarate also depends on extracellular pH, as fumarate is a weak inhibitor at pHo 6 and shows no agonist action at neutral pHo. A mutational analysis of residue dependency for succinate and fumarate effects, based on two carboxylate-binding pockets previously identified by crystallography (Fourati et al., 2020), shows that positive modulation involves both the inter-subunit pocket, homologous to the neurotransmitter-binding orthotopic site, and the intra-subunit (also called vestibular) pocket. An almost similar pattern of mutational impact is observed for the effect of caffeate, a known negative modulator. We propose, for both dicarboxylate compounds and caffeate, a model where the inter-subunit pocket is the actual binding site, and the region corresponding to the vestibular pocket is required either for inter-subunit binding itself, or for binding-to-gating coupling during the allosteric transitions involved in pore-gating modulation.
- 27 April 2023
- Published by Wiley in The Journal of Physiology
- Vol. 601 (12) , 2447-2472
Fumarate as positive modulator of allosteric transitions in the pentameric ligand‐gated ion channel GLIC: requirement of an intact vestibular pocket
Gloeobacter violaceus ligand-gated ion channel (GLIC) is a prokaryotic orthologue of brain pentameric neurotransmitter receptors. Using whole-cell patch-clamp electrophysiology in a host cell line, we show that short-chain dicarboxylate compounds are positive modulators of pHo 5-evoked GLIC activity, with a rank order of action fumarate > succinate > malonate > glutarate. Potentiation by fumarate depends on intracellular pH, mainly as a result of a strong decrease of the pHo 5-evoked current when intracellular pH decreases. The modulating effect of fumarate also depends on extracellular pH, as fumarate is a weak inhibitor at pHo 6 and shows no agonist action at neutral pHo. A mutational analysis of residue dependency for succinate and fumarate effects, based on two carboxylate-binding pockets previously identified by crystallography (Fourati et al., 2020), shows that positive modulation involves both the inter-subunit pocket, homologous to the neurotransmitter-binding orthotopic site, and the intra-subunit (also called vestibular) pocket. An almost similar pattern of mutational impact is observed for the effect of caffeate, a known negative modulator. We propose, for both dicarboxylate compounds and caffeate, a model where the inter-subunit pocket is the actual binding site, and the region corresponding to the vestibular pocket is required either for inter-subunit binding itself, or for binding-to-gating coupling during the allosteric transitions involved in pore-gating modulation.
- Open Access
Short-chain mono-carboxylates as negative modulators of allosteric transitions in GLIC, and impact of a pre-β5 strand (Loop Ω) double mutation on crotonate, not butyrate effect
The bacterial model GLIC remains one of the best known among pentameric ligand-gated ion channels (pLGICs), regarding their structure. GLIC is activated at low extracellular pH, but no agonist compound is known. Van Renterghem et al . (2023) showed that short-chain di-carboxylates potentiate GLIC activity, with strict dependence on two carboxylate binding pockets, previously characterized by crystallography (Sauguet et al ., 2013, Fourati et al ., 2015, 2020). An “in series” model was proposed, with compound binding at the inter-subunit pocket [homologous to the pLGICs orthotopic neutotransmitter binding site], and with involvement of the intra-subunit (or vestibular) pocket in coupling binding to gating. Here we characterize saturated, mono-carboxylates as negative modulators of GLIC, as previously shown for crotonate (Alqazzaz et al ., 2016). Butyrate and crotonate have indistinguishable properties regarding negative modulation of WT GLIC. However, a double mutation in the pre-β5 strand (Loop Ω) converts crotonate, as well as caffeate, but not butyrate, into positive modulators. We perform a mutational analysis of residue dependency in the two pockets, with the pre-β5 strand either intact or mutated. We propose that positive modulation requires stringent conditions, with integrity of both pockets, whereas negative modulation is less labile. The vestibular pocket may be involved as an accessory binding site leading to negative, but not positive modulation. We propose that the pre-β5 strand is involved in ligand-elicited modulation of GLIC gating, not in pHo-controlled gating. Possible involvement in Eukaryote pLGICs of regions corresponding to the vestibular pocket and the pre-β5 strand/Loop Ω is discussed. Key points summary: Using the bacterial proton-activated receptor-channel GLIC, we identify a locus in the pre-β5 strand (Loop Ω) whose mutation inverses the effect of the mono-carboxylate crotonate from negative to positive modulation of the allosteric transitions, suggesting an involvement of the pre-β5 strand in coupling the extracellular orthotopic receptor to pore gating in this pentameric ligand-gated ion channel. As an extension to the previously proposed “in series” mechanism, we suggest that a orthotopic/orthosteric site – vestibular site – Loop Ω – β5-β6 “sandwich” - Pro-Loop/Cys-Loop series may be an essential component of orthotopic/orthosteric compound-elicited gating control in this pentameric ligand-gated ion channel, on top of which compounds targeting the vestibular site may provide modulation.
Open AccessShort-chain mono-carboxylates as negative modulators of allosteric transitions in GLIC, and impact of a pre-β5 strand (Loop Ω) double mutation on crotonate, not butyrate effect
The bacterial model GLIC remains one of the best known among pentameric ligand-gated ion channels (pLGICs), regarding their structure. GLIC is activated at low extracellular pH, but no agonist compound is known. Van Renterghem et al . (2023) showed that short-chain di-carboxylates potentiate GLIC activity, with strict dependence on two carboxylate binding pockets, previously characterized by crystallography (Sauguet et al ., 2013, Fourati et al ., 2015, 2020). An “in series” model was proposed, with compound binding at the inter-subunit pocket [homologous to the pLGICs orthotopic neutotransmitter binding site], and with involvement of the intra-subunit (or vestibular) pocket in coupling binding to gating. Here we characterize saturated, mono-carboxylates as negative modulators of GLIC, as previously shown for crotonate (Alqazzaz et al ., 2016). Butyrate and crotonate have indistinguishable properties regarding negative modulation of WT GLIC. However, a double mutation in the pre-β5 strand (Loop Ω) converts crotonate, as well as caffeate, but not butyrate, into positive modulators. We perform a mutational analysis of residue dependency in the two pockets, with the pre-β5 strand either intact or mutated. We propose that positive modulation requires stringent conditions, with integrity of both pockets, whereas negative modulation is less labile. The vestibular pocket may be involved as an accessory binding site leading to negative, but not positive modulation. We propose that the pre-β5 strand is involved in ligand-elicited modulation of GLIC gating, not in pHo-controlled gating. Possible involvement in Eukaryote pLGICs of regions corresponding to the vestibular pocket and the pre-β5 strand/Loop Ω is discussed. Key points summary: Using the bacterial proton-activated receptor-channel GLIC, we identify a locus in the pre-β5 strand (Loop Ω) whose mutation inverses the effect of the mono-carboxylate crotonate from negative to positive modulation of the allosteric transitions, suggesting an involvement of the pre-β5 strand in coupling the extracellular orthotopic receptor to pore gating in this pentameric ligand-gated ion channel. As an extension to the previously proposed “in series” mechanism, we suggest that a orthotopic/orthosteric site – vestibular site – Loop Ω – β5-β6 “sandwich” - Pro-Loop/Cys-Loop series may be an essential component of orthotopic/orthosteric compound-elicited gating control in this pentameric ligand-gated ion channel, on top of which compounds targeting the vestibular site may provide modulation.
- Open Access
Generation of nanobodies acting as silent and positive allosteric modulators of the α7 nicotinic acetylcholine receptor
The α7 nicotinic acetylcholine receptor (nAChR), a potential drug target for treating cognitive disorders, mediates communication between neuronal and non-neuronal cells. Although many competitive antagonists, agonists, and partial-agonists have been found and synthesized, they have not led to effective therapeutic treatments. In this context, small molecules acting as positive allosteric modulators binding outside the orthosteric, acetylcholine, site have attracted considerable interest. Two single-domain antibody fragments, C4 and E3, against the extracellular domain of the human α7-nAChR were generated through alpaca immunization with cells expressing a human α7-nAChR/mouse 5-HT 3 A chimera, and are herein described. They bind to the α7-nAChR but not to the other major nAChR subtypes, α4β2 and α3β4. E3 acts as a slowly associating positive allosteric modulator, strongly potentiating the acetylcholine-elicited currents, while not precluding the desensitization of the receptor. An E3-E3 bivalent construct shows similar potentiating properties but displays very slow dissociation kinetics conferring quasi-irreversible properties. Whereas, C4 does not alter the receptor function, but fully inhibits the E3-evoked potentiation, showing it is a silent allosteric modulator competing with E3 binding. Both nanobodies do not compete with α-bungarotoxin, localizing at an allosteric extracellular binding site away from the orthosteric site. The functional differences of each nanobody, as well as the alteration of functional properties through nanobody modifications indicate the importance of this extracellular site. The nanobodies will be useful for pharmacological and structural investigations; moreover, they, along with the extracellular site, have a direct potential for clinical applications.
Open AccessGeneration of nanobodies acting as silent and positive allosteric modulators of the α7 nicotinic acetylcholine receptor
The α7 nicotinic acetylcholine receptor (nAChR), a potential drug target for treating cognitive disorders, mediates communication between neuronal and non-neuronal cells. Although many competitive antagonists, agonists, and partial-agonists have been found and synthesized, they have not led to effective therapeutic treatments. In this context, small molecules acting as positive allosteric modulators binding outside the orthosteric, acetylcholine, site have attracted considerable interest. Two single-domain antibody fragments, C4 and E3, against the extracellular domain of the human α7-nAChR were generated through alpaca immunization with cells expressing a human α7-nAChR/mouse 5-HT 3 A chimera, and are herein described. They bind to the α7-nAChR but not to the other major nAChR subtypes, α4β2 and α3β4. E3 acts as a slowly associating positive allosteric modulator, strongly potentiating the acetylcholine-elicited currents, while not precluding the desensitization of the receptor. An E3-E3 bivalent construct shows similar potentiating properties but displays very slow dissociation kinetics conferring quasi-irreversible properties. Whereas, C4 does not alter the receptor function, but fully inhibits the E3-evoked potentiation, showing it is a silent allosteric modulator competing with E3 binding. Both nanobodies do not compete with α-bungarotoxin, localizing at an allosteric extracellular binding site away from the orthosteric site. The functional differences of each nanobody, as well as the alteration of functional properties through nanobody modifications indicate the importance of this extracellular site. The nanobodies will be useful for pharmacological and structural investigations; moreover, they, along with the extracellular site, have a direct potential for clinical applications.
- Open Access
- 1 April 2009
- Published by Wiley in The FASEB Journal
- Vol. 23 (S1) , 942.4
Alpha‐7 Nicotinic Acetylcholine Receptor (nAChR) Characteristics on the Acetylcholine Binding Protein
The cys‐loop family of ligand‐gated ion channels plays an important role in the chemical‐to‐electrical transduction of neuronal signaling. The well‐studied α7‐nAChR may be linked to nicotine addiction, and shows possible genetic linkages to such diseases as Alzheimer's and schizophrenia. The discovery of a homologous soluble snail acetylcholine binding protein (AChBP) provided a structural surrogate of the extracellular ligand‐binding domain; however, the binding protein, despite the requisite ligand properties, shows only 30% residue identity with the nicotinic receptor family. Here we show systematic mutations of the soluble Aplysia californica towards the α7‐nAChR with simultaneous analysis of binding affinities. Key constructs were subsequently characterized using classical α7‐nAChR selective ligands such as α‐bungarotoxin, (+)‐epibatidine, and methyllycaconitine, as well as crystal structures have been obtained for some of the intermediate constructs. (Support: U01‐NS 05846, GM07752‐29)
- 1 April 2009
- Published by Wiley in The FASEB Journal
- Vol. 23 (S1) , 942.4
Open AccessAlpha‐7 Nicotinic Acetylcholine Receptor (nAChR) Characteristics on the Acetylcholine Binding Protein
The cys‐loop family of ligand‐gated ion channels plays an important role in the chemical‐to‐electrical transduction of neuronal signaling. The well‐studied α7‐nAChR may be linked to nicotine addiction, and shows possible genetic linkages to such diseases as Alzheimer's and schizophrenia. The discovery of a homologous soluble snail acetylcholine binding protein (AChBP) provided a structural surrogate of the extracellular ligand‐binding domain; however, the binding protein, despite the requisite ligand properties, shows only 30% residue identity with the nicotinic receptor family. Here we show systematic mutations of the soluble Aplysia californica towards the α7‐nAChR with simultaneous analysis of binding affinities. Key constructs were subsequently characterized using classical α7‐nAChR selective ligands such as α‐bungarotoxin, (+)‐epibatidine, and methyllycaconitine, as well as crystal structures have been obtained for some of the intermediate constructs. (Support: U01‐NS 05846, GM07752‐29)